Pravastatin vs lipitor

Common Questions and Answers about Pravastatin vs lipitor

pravachol

The risk of rhabdomyolysis by the use of any statin is .044% and deaths from rhabdomyolysis occur in 1 prescription out of every 20 MILLION prescriptions.From the Journal of the American Medical Association (JAMA);
"Average incidence per 10 000 person-years for monotherapy with atorvastatin, pravastatin, or simvastatin was 0.44%"
Here's the link;
http://jama.ama-assn.org/content/292/21/2585.

After 36 weeks of treatment, the cumulative proportion of patients who reached the primary safety endpoint was lower in the pravastatin group than in the placebo group (8% vs 13%; 95% confidence interval [CI], −11.6 to 1.6; P = .1379). In fact, the mean ALT values declined from baseline in the pravastatin group, whereas the mean ALT and AST were increased from baseline in the placebo group. None of the subjects in either treatment group had an elevation of total bilirubin >2 times the ULN.

For what it's worth, from a recent study done in Japan;
A 6-month prospective observational study was conducted with 84 CAD patients receiving pravastatin treatment in order to evaluate the relationship between lifestyle modification, in particular aerobic exercise, and plaque volume as assessed by intravascular ultrasound (IVUS). Lifestyle during the study period was assessed by the-lifestyle modification score. A significant decrease in plaque volume by 12.

Has anyone read how horrific the side effects really are to some of these statins and realized that either they or their loved ones had these very symtoms and becames seriously ill to the point that they ended up in ICU not knowing who they were, where they were, in so much pain they could not bear to be touched and had regressed to near infancy before anyone figured out that it was zocor or lipitor or another statin they were on that was causing these bizarre illnessess ?

They found that among HCV positive individuals, use of statins was associated with a higher rate of mild-to-moderate liver biochemistry elevations compared with those not on statins (23% vs 13%, respectively), but a lower incidence of severe liver enzyme elevations (1% vs 7%).
Among patients started on statins, the rates of mild-to-moderate elevations were similar in subjects with and without HCV (23% vs 16%, respectively).

The Content on this Site is presented in a summary fashion, and is intended to be used for educational and entertainment purposes only. It is not intended to be and should not be interpreted as medical advice or a diagnosis of any health or fitness problem, condition or disease; or a recommendation for a specific test, doctor, care provider, procedure, treatment plan, product, or course of action. Med Help International, Inc. is not a medical or healthcare provider and your use of this Site does not create a doctor / patient relationship. We disclaim all responsibility for the professional qualifications and licensing of, and services provided by, any physician or other health providers posting on or otherwise referred to on this Site and/or any Third Party Site. Never disregard the medical advice of your physician or health professional, or delay in seeking such advice, because of something you read on this Site. We offer this Site AS IS and without any warranties. By using this Site you agree to the following Terms and Conditions. If you think you may have a medical emergency, call your physician or 911 immediately.